Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
Global Melanoma Therapeutics Market 2012-2016

Global melanoma therapeutics market: 16% CAGR between 2012-2016


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-02-18 19:50:03 - Global Melanoma Therapeutics Market 2012-2016 - a new market research report on companiesandmarkets.com

The Global Melanoma Therapeutics market is to grow at a CAGR of 15.83 percent over the period 2012-2016. One of the key factors contributing to this market growth is the availability of new promising drugs in the pipeline. The Global Melanoma Therapeutics market has also been witnessing the increasing use of combination therapies for the treatment of melanoma. However, the availability of alternative treatment options could pose a challenge to the growth of this market.

A current trend witnessed in the Global Melanoma Therapeutics market is the use of combination therapies for the treatment of melanoma. At stage IV of melanoma, tumor cells spread from its origin site to distant sites. Thus, it cannot be cured with the help of one

 

 

single therapy alone. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapies help in the complete removal of tumors and the destruction of cancerous cells. For instance, chemotherapy combined with immunotherapy is the most promising therapy available for the treatment of metastatic melanoma. The combination is chosen according to the size of the tumor and the risk of recurrence.

One of the major drivers is the presence of new promising drugs in the pipeline. There were only three drugs in the market till 2011. With the launch of three new drugs in 2011, the market size increased considerably. Thus, with more drugs in the pipeline, the market will experience positive growth in the future.

The biggest challenge that the Global Melanoma Therapeutics market is facing is the availability of alternative treatment options other than drugs such as surgery and radiation therapy. These alternative treatments limit the consumption of drugs.

The key vendors dominating this market space are Bristol-Myers Squibb Co., Merck and Co. Inc., and F. Hoffmann-La Roche Ltd. The other vendors mentioned in the report are AB Science S.A., Amgen Inc., Celgene Corp., Daiichi Sankyo Co., Eisai Co. Ltd., GlaxoSmithKline plc, Pfizer Inc., and Vical Inc.

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser